A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM

The purpose of the study is to test the safety and efficacy of iberdomide in a larger number of patients. Iberdomide is not FDA approved for the treatment of any disease. This study will also assess how patients feel about the multiple myeloma treatment received in this study, and their quality of life as it relates to their health. Iberdomide is a medication taken by mouth that binds to a protein known as cereblon, which may result in the destruction of specific proteins by the body. This study drug may modify or regulate the functioning of the immune system and may induce the destruction of proteins that are important to keep myeloma cells alive. This may lead to the breakdown of the multiple myeloma cells.

Are you Eligible? (Inclusion Criteria)

• Are at least 18 years of age - Have been diagnosed with multiple myeloma and either recommended for, or started with intensive treatment including bone marrow transplant - Achieved at least a partial response after bone marrow transplant